Picture EBD Group Global Partnering Four Events One Price 650x80
Organisation › Details

Handl Therapeutics B.V.

The vision of Handl Therapeutics is to deploy the power of disease modifying in vivo gene therapy to treat complex neurodegenerative diseases to begin addressing significant unmet medical needs in healthcare. The innovative business model is based on a highly integrative approach that is built on tight links with an international network of academic partners. Handl Therapeutics goal is to build a streamlined business that is designed to deliver transformative advanced medicines to the market. *


Period Start 2019-10-01 established
  Group UCB (Group)
Products Industry BIOTECH
  Industry 2 gene therapy
Region Region Leuven (Louvain)
  Country Belgium
  Street 1 Gaston Geenslaan
Bio-Incubator 3
  City 3001 Heverlee
  Tel +32-470-555311
    Address record changed: 2020-12-02
Basic data Employees n. a.
    * Document for �About Section�: UCB S.A.. (11/12/20). "Press Release: UCB Strengthens Its Gene Therapy Activities with Additional Pipeline Programs, Capabilities and Platforms". Brussels.
Record changed: 2020-11-18


Picture BIO Deutschland German Corona Special 2021 Digital 650x80px

More documents for UCB (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group ChinaBio Partnerting Forum 2021 651x80

» top